Breakthrough infections in MPN-COVID vaccinated patients - Summary - MDSpire

Breakthrough infections in MPN-COVID vaccinated patients

  • By

  • Tiziano Barbui

  • Alessandra Carobbio

  • Arianna Ghirardi

  • Alessandra Iurlo

  • Valerio De Stefano

  • Marta Anna Sobas

  • Elisa Rumi

  • Elena Maria Elli

  • Francesca Lunghi

  • Mercedes Gasior Kabat

  • Beatriz Cuevas

  • Paola Guglielmelli

  • Massimiliano Bonifacio

  • Monia Marchetti

  • Alberto Alvarez-Larran

  • Laura Fox

  • Marta Bellini

  • Rosa Daffini

  • Giulia Benevolo

  • Gonzalo Carreno-Tarragona

  • Andrea Patriarca

  • Haifa Kathrin Al-Ali

  • Maria Marcio Miguel Andrade-Campos

  • Francesca Palandri

  • Claire Harrison

  • Maria Angeles Foncillas

  • Santiago Osorio

  • Steffen Koschmieder

  • Elena Magro Mazo

  • Jean-Jacques Kiladjian

  • Estefanía Bolaños Calderón

  • Florian H. Heidel

  • Keina Quiroz Cervantes

  • Martin Griesshammer

  • Valentin Garcia-Gutierrez

  • Alberto Marin Sanchez

  • Juan Carlos Hernandez-Boluda

  • Emma Lopez Abadia

  • Giuseppe Carli

  • Miguel Sagues Serrano

  • Rajko Kusec

  • Blanca Xicoy Cirici

  • Margarita Guenova

  • Begona Navas Elorza

  • Anna Angona

  • Edyta Cichocka

  • Anna Kulikowska de Nałęcz

  • Daniele Cattaneo

  • Cristina Bucelli

  • Silvia Betti

  • Oscar Borsani

  • Fabrizio Cavalca

  • Sara Carbonell

  • Natalia Curto-Garcia

  • Lina Benajiba

  • Alessandro Rambaldi

  • Alessandro Maria Vannucchi

  • November 15, 2022

  • 0 min

Share

Objective:

To investigate the incidence and severity of COVID-19 breakthrough infections in vaccinated patients with myeloproliferative neoplasms (MPN).

Key Findings:
  • Include mention of statistical significance where applicable.
Interpretation:

Specify which MPN subtypes are most affected by lower vaccine effectiveness.

Limitations:
  • Add a limitation regarding sample diversity.
Conclusion:

Reiterate the clinical implications of breakthrough infections in MPN patients.

Original Source(s)

Breakthrough infections in MPN-COVID vaccinated patients

  • by Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Alessandra Iurlo, Valerio De Stefano, Marta Anna Sobas, Elisa Rumi, Elena Maria Elli, Francesca Lunghi, Mercedes Gasior Kabat, Beatriz Cuevas, Paola Guglielmelli, Massimiliano Bonifacio, Monia Marchetti, Alberto Alvarez-Larran, Laura Fox, Marta Bellini, Rosa Daffini, Giulia Benevolo, Gonzalo Carreno-Tarragona, Andrea Patriarca, Haifa Kathrin Al-Ali, Maria Marcio Miguel Andrade-Campos, Francesca Palandri, Claire Harrison, Maria Angeles Foncillas, Santiago Osorio, Steffen Koschmieder, Elena Magro Mazo, Jean-Jacques Kiladjian, Estefanía Bolaños Calderón, Florian H. Heidel, Keina Quiroz Cervantes, Martin Griesshammer, Valentin Garcia-Gutierrez, Alberto Marin Sanchez, Juan Carlos Hernandez-Boluda, Emma Lopez Abadia, Giuseppe Carli, Miguel Sagues Serrano, Rajko Kusec, Blanca Xicoy Cirici, Margarita Guenova, Begona Navas Elorza, Anna Angona, Edyta Cichocka, Anna Kulikowska de Nałęcz, Daniele Cattaneo, Cristina Bucelli, Silvia Betti, Oscar Borsani, Fabrizio Cavalca, Sara Carbonell, Natalia Curto-Garcia, Lina Benajiba, Alessandro Rambaldi, Alessandro Maria Vannucchi

  • November 15, 2022

Related Content

Pediatric Acute Respiratory Virus Hospitalizations: A Population-Based Cohort Study, 2017–2024

Viral infections and risk, in Wine and Medicine

Persistence of an Infectious Form of SARS-CoV-2 After Protease Inhibitor Treatment of Permissive Cells In Vitro